Shares News

Why Card Factory shares folded despite resilient first half sales and reiterated full year guidance featured picture

Why Card Factory shares folded despite resilient first half sales and reiterated full year guidance

Following a stunning run into the numbers, shares in Card Factory (CARD) cheapened 16% to 121p after the value-focused greeting cards-to-party supplies retailer delivered a drop in first half earnings and warned full year profits will be second half weighted. While some investors took profits on the unnerving news, Card Factory actually delivered robust first half sales with all channels in gro...
AstraZeneca’s cancer drug shows no improvement in overall survival rates featured picture

AstraZeneca’s cancer drug shows no improvement in overall survival rates

Anglo-Swedish pharmaceutical giant AstraZeneca (AZN) was on the back foot on Monday after reporting disappointing late-stage trial results for Dato-DXd, its precision advanced breast cancer experimental drug. The news sent the shares down 1.4% to £116.10, a new three month low and follows fast on the heels of similarly disappointing results from lung cancer trials released in August. WHY WERE...
FTSE closes in the red as downbeat consumer confidence data offset rate cut featured picture

FTSE closes in the red as downbeat consumer confidence data offset rate cut

The FTSE 100 and 250 closed in the red on Friday, as this week's US interest rate cut was offset by a disappointing consumer confidence reading. The FTSE 100 index closed down 98.73 points, or 1.2%, at 8,229.99. The FTSE 250 ended down 330.87 points, or 1.6%, at 20,831.84, and the AIM All-Share closed down 0.3%, or 2.46 points, at 745.62. The Cboe UK 100 ended down 1.2% at 823.77, the Cboe UK 2...
AstraZeneca director snaps up shares after one-month low, Computacenter and Essentra directors buy| Director Deals featured picture

AstraZeneca director snaps up shares after one-month low, Computacenter and Essentra directors buy| Director Deals

Michael Demare, non-executive chair of pharmaceutical giant AstraZeneca (AZN) has bought 2,000 shares at £117.93 for a total value of £235,855 on 13 September. Demare's move comes after the pharmaceutical giant's shares recently fell to a one-month low after the UK's largest quoted company released disappointing data from a late-stage clinical trial of its precision lung-cancer drug DatoDxD....
Showing 1 to 13 of 15,292